Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial

Keros Therapeutics anticipates a $20 million development milestone payment from Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial, which evaluates elritercept for myelofibrosis. The global license agreement with Takeda, effective January 16, 2025, includes a $200 million upfront payment and potential total milestones exceeding $1.1 billion. Keros plans to distribute 25% of the net cash proceeds from this milestone payment to its stockholders.